Your browser doesn't support javascript.
loading
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.
Blackhall, Fiona; Ross Camidge, D; Shaw, Alice T; Soria, Jean-Charles; Solomon, Benjamin J; Mok, Tony; Hirsh, Vera; Jänne, Pasi A; Shi, Yuankai; Yang, Pan-Chyr; Pas, Tommaso De; Hida, Toyoaki; Carpeño, Javier De Castro; Lanzalone, Silvana; Polli, Anna; Iyer, Shrividya; Reisman, Arlene; Wilner, Keith D; Kim, Dong-Wan.
Afiliação
  • Blackhall F; Institute of Cancer Sciences, Manchester University and Christie Hospital NHS Foundation Trust, Manchester, UK.
  • Ross Camidge D; Division of Oncology, University of Colorado Comprehensive Cancer Center, Aurora, Colorado, USA.
  • Shaw AT; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, , Massachusetts, USA.
  • Soria JC; Department of Medical Oncology, Institut Gustave Roussy, Paris, France.
  • Solomon BJ; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Mok T; State Key Laboratory of South China, Hong Kong Cancer Institute and The Chinese University of Hong Kong, Shatin, China.
  • Hirsh V; Division of Medical Oncology, McGill University Health Centre, Montreal, Canada.
  • Jänne PA; Lowe Center for Thoracic Oncology, The Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Shi Y; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Yang PC; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Pas T; Department of Oncology, European Institute of Oncology, Milan, Italy.
  • Hida T; Department of Thoracic Oncology, Aichi Cancer Center Central Hospital, Nagoya, Japan.
  • Carpeño JC; Medical Oncology Service, Hospital Universitario La Paz, Madrid, Spain.
  • Lanzalone S; Pfizer Oncology, Milan, Italy.
  • Polli A; Pfizer Oncology, Milan, Italy.
  • Iyer S; Pfizer Oncology, New York, New York, USA.
  • Reisman A; Pfizer Global Innovative Pharma Business, New York, New York, USA.
  • Wilner KD; Pfizer Oncology, La Jolla, California, USA.
  • Kim DW; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
ESMO Open ; 2(3): e000219, 2017.
Article em En | MEDLINE | ID: mdl-29209525
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2017 Tipo de documento: Article